Latest News
- April 18, 2025Attending AACR 2025 Annual Meeting (25 – 30 April 2025, Chicago, IL)
- April 04, 2025Attending the 40th Asia-Pacific Academy of Ophthalmology (APAO) Congress
- March 31, 2025Accelerating Clinical Research!
- March 27, 2025Innovating for Better Vision: Ocuvex Therapeutics in Ophthalmology
- March 17, 2025Join CBCC Global Research at these exciting In-Person Events in Q2 2025
January 07, 2024
We welcome Dr David Bearss to our strategic advisory board
We are pleased to announce the induction of David Bearss Ph.D. to our strategic advisory board as a key advisor for clinical trials.
Dr. David Bearss is the CEO of Halia Therapeutics, Inc. He is an experienced entrepreneur and drug developer with 20 plus years of experience in academic and industry settings.
We are confident that Dr. Bearss’ comprehensive understanding of the drug development life cycle and technical expertise in all aspects of patient care will add immeasurable value to our Customer’s Clinical Development Plans.
CBCC Global Research: CHANGING LIVES THROUGH HOPE AND INNOVATION
